Summary
Entegris, Inc. (ENTG) announced a change to its Board of Directors with the appointment of Dr. Azita Saleki-Gerhardt, effective August 14, 2017. Dr. Saleki-Gerhardt's appointment is a key development for investors to note, as it suggests the board is being strengthened with new expertise. While no specific details on her background are provided in this 8-K, such appointments often signal strategic considerations or a desire to broaden the board's skill set to better guide the company. Dr. Saleki-Gerhardt will receive standard compensation for non-employee directors, including a prorated award of restricted stock units (3,897 RSUs) and an annual retainer. The restricted stock units vest based on the 2018 Annual Meeting of Stockholders or the first anniversary of the award. Investors should monitor the performance of these RSUs as an indicator of management and board alignment with shareholder value creation. The company will also enter into an indemnity agreement, which is standard practice for directors.
Key Highlights
- 1Entegris appointed Azita Saleki-Gerhardt, Ph.D. as a new director to its Board, effective August 14, 2017.
- 2Dr. Saleki-Gerhardt's appointment was not based on any specific arrangement or understanding with other parties.
- 3She will receive prorated compensation as a non-employee director, including a $75,000 annual retainer (paid quarterly).
- 4A prorated award of 3,897 restricted stock units (RSUs) was granted to Dr. Saleki-Gerhardt, with restrictions lapsing on the earlier of the 2018 Annual Meeting or the first anniversary of the award.
- 5The company plans to enter into a standard indemnity agreement with Dr. Saleki-Gerhardt.
- 6There are no reportable transactions between Entegris and Dr. Saleki-Gerhardt under Item 404(a) of Regulation S-K.
- 7A press release announcing the appointment is attached as an exhibit.